Abstract
Purpose Stereotactic radiosurgery (SRS) is used to manage intracranial metastases in a significant fraction of patients. Local progression after SRS can often only be detected with increased volume of enhancement on serial MRI scans which may lag true progression by weeks or months.
Experimental Design Patients with intracranial metastases (N = 11) were scanned using hyperpolarized 13C MRI prior to treatment with stereotactic radiosurgery (SRS). The status of each lesion was then recorded at six months post-treatment follow-up (or at the time of death).
Results The positive predictive value of 13C-lactate signal, measured pre-treatment, for prediction of progression of intracranial metastases at six months post-treatment with SRS was 0.8 p < 0.05, and the AUC from an ROC analysis was 0.77 p < 0.05. The distribution of 13C-lactate z-scores was different for intracranial metastases from different primary cancer types (F = 2.46, p = 0.1).
Conclusions Hyperpolarized 13C imaging has potential as a method for improving outcomes for patients with intracranial metastases, by identifying patients at high risk of treatment failure with SRS and considering other therapeutic options such as surgery.
Competing Interest Statement
Dr. Chen is an employee of GE Healthcare Arjun Sahgal's Disclosures: Advisor/consultant with AbbVie, Merck, Roche, Varian (Medical Advisory Group), Elekta (Gamma Knife Icon), BrainLAB, and VieCure (Medical Advisory Board) Board Member: International Stereotactic Radiosurgery Society (ISRS) Co-Chair: AO Spine Knowledge Forum Tumor Past educational seminars with Elekta AB, Accuray Inc., Varian (CNS Teaching Faculty), BrainLAB, Medtronic Kyphon Research grant with Elekta AB Travel accommodations/expenses by Elekta, Varian, BrainLAB
Clinical Trial
NCT03324360
Funding Statement
This work was funded by Brain Canada, the Canadian Cancer Society Research Institute and the Canadian Institutes for Cancer Research PJT-152928
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Approval was granted by the Research Ethics Board at Sunnybrook Health Sciences Centre, and by Health Canada.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data will be made available upon reasonable request to the authors.
Abbreviations
- DE-EPI
- dual-echo echo-planar imaging
- HP
- hyperpolarization
- kpl
- forward kinetic rates of pyruvate-to-lactate conversion
- Lac/Pyr
- ratio between intensities of 13C-lactate and 13C-pyruvate signals
- Lac/Bic
- ratio between intensities of 13C-lactate and 13C-bicarbonate signals
- NSLSC
- non-small cell lung cancer
- RCC
- renal cell carcinoma
- ROC
- receiver operating characteristic
- W
- coefficient of Kendall’s concordance
